2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö : 2024-06-08
±³À°ÀÏÀÚ : 2024-06-08
±³À°Àå¼Ò : È£ÅÚ¸®º£¶óû´ã º£¸£»çÀÌÀ¯È¦
±³À°ÁÖÁ¦ : 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í ºñȸ¿ø 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 14:00~14:20 Standard risk ALL(acute lymphoblastic leukemia) ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 14:20~14:50 Very high risk ALL(acute lymphoblastic leukemia) ±èº¸°æ(¼¿ïÀÇ´ë )
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 14:50~15:10 Relapsed ALL(acute lymphoblastic leukemia) ±èÇý¸®(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 15:10~15:25 °í¿ë·® methotrexate µ¶¼º ¿¹¹æÀ» À§ÇÑ glucarpidase Àӻ󿬱¸ ÃÖÁ¤À±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 15:25~15:40 ¼Ò¾Æ ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ Ä¡·áÀÇ ÁËÀûȸ¦ À§ÇÑ Ç×¾ÏÁ¦ Therapeutic Drug Monitoring Àӻ󿬱¸°³¹ß ±èÇý¸®(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 15:40~15:55 ¼Ò¾Æ ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¸é¿ªÄ¡·á ¿¬°ü µ¶¼º Ä¡·áÁ¦ anakinraÀÇ È¿¿ë¼º Æò°¡ À¯Àç¿ø(°¡Å縯ÀÇ´ë )
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 16:30~17:00 The genomic landscape in pediatric ALL(acute lymphoblastic leukemia) ¹éÈñÁ¶(Àü³²ÀÇ´ë )
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 17:00~17:30 Current state of precision medicine in pediatric ALL(acute lymphoblastic leukemia) ½É¿¹Áö(°è¸íÀÇ´ë )
±³À°½Ã°£ 06¿ù 08ÀÏ 1°ÀÇ½Ç 17:30~18:00 What¡¯s new in immunotherapy in pediatric ALL(acute lymphoblastic leukemia) ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë )